DarioHealth, a digital chronic-condition management platform, announced a collaboration with an unnamed pharma company that will leverage DarioConnect (formerly Twill Care) to advance its direct-to-consumer initiatives using Dario's engagement and navigation technologies.

The aim of the alliance is to gather critical insights on patient outcomes and drug effectiveness with Dario Connect's community-building capabilities, thereby playing a role in increasing patient engagement.

The drug company, in an effort to fortify and broaden connections across patient populations that are candidates for a new drug to treat psoriasis, plans to use Dario to pilot an initiative aimed to help onboard patients via the platform who will engage with the drug. 

As part of the contract, a participating consumer health platform will work in concert with the pharma company to authorize patients to aggregate all of their medical records in one place. 

This would allow the pharmaceutical companies to access de-identified, aggregate data to monitor patient outcomes and gain an understanding into prescription trends for the drug. 

Regarding the financial formation of the collaboration, Dario will begin with a fixed configuration fee that will be followed by a platform-and-services subscription fee structure that permits Dario Connect to continue to steer engaged patients directly to the pharma company's digital environment.

"Dario Connect's advanced approach aims to redefine how pharmaceutical companies engage with patients, offering unparalleled opportunities for data-driven insights and patient support that can shape the future of healthcare," Steven Nelson, chief commercial officer at DarioHealth, said in a statement.

THE LARGER TREND

In September, DarioHealth announced the integration of Twill's condition-specific communities and peer groups with customized navigation expertise into its cardiometabolic platform. 

DarioHealth acquired digital therapeutics company Twill in February, accompanied by a $22.4 million equity financing. The combination gave Dario the ability to create a comprehensive digital offering in the market for chronic conditions, covering a wide spectrum of health and wellbeing needs from emotional health to the most expensive chronic conditions.

Last month, Dario entered into a contract with a national Medicare Advantage health plan and announced that it plans to launch its behavioral health initiative, Twill by Dario, for the plan's members in Jan. 2025. 

The company said it expects the multimillion-dollar Medicare Advantage contract to contribute substantially to its annual recurring revenue growth in the company's B2B2C channel in 2025. 

DarioHealth also announced a new contract with a regional health plan in the Medicaid space, which was launched with a full suite of cardiometabolic solutions. 

DarioHealth reported its Q2 2024 earnings in August, citing total revenue of $6.26 million, a 1.7% increase compared to Q2 2023, driven mainly by B2B2C revenues. 

The company's commercial and consumer revenues totaled $7.34 million "before a non-recurring price concession in collaboration with a pharma partner," which represents a 105% increase, compared to the $3.57 million seen in the second quarter of the previous year.